Diasome Pharmaceuticals, Inc.

Diasome is developing Oral HDV-Insulin, a nanotechnology-based cell targeting system for the improved treatment of diabetes mellitus. Diasome's therapies have been tested in more than 100 subjects to date. The Company is preparing to conduct longer term clinical trials in 2008 after having held an end of Phase II meeting with the FDA in 2007.

Website

625 Ridge Pike, Building E, Suite 402
Conshohocken, PA 19428 USA
610-834-2700